Cytotoxics And High Potency Manufacturing

Capsules | Cytotoxics and High Potency Manufacturing | Solid Dosage/Creams/Ointments | Solid Dosage/Semi-solids

Multi-particulate Formulations – Tablets or Capsules?

Multiple-unit dosage forms are gaining significant popularity among drug developers due to their benefits.

Subhashis Chakraborty and Ananya Sen, ACG 03.11.24

Cytotoxics and High Potency Manufacturing | Drug Development

Trends in the Development of ADCs

Targeting tumor heterogeneity with antibody-drug conjugates and novel payloads.

Louise Duffy, Chief Technical Officer, Abzena 02.01.24

Cytotoxics and High Potency Manufacturing | Drug Development | Process Development

HPAPI Trends: Drug Synthesis in Early Development

Addressing the challenge of new clinical targets and highly potent compounds.

Rob Abbenhuis, Chemistry Division Manager, Ardena 02.01.24

cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Drug Development | Fill/Finish | Information Technology

Calling All Laureates in Oncology Drug Manufacturing

Leveraging technology to reduce development timelines while maintaining safety will be key to delivering critical oncology products.

Rebecca Coutts, General Manager, PCI Pharma Services 02.01.24

APIs | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing

Olon Group to Add New High Potency API Suite in Ohio

Expands its capabilities to serve clients developing innovative therapies for cancer, rare diseases and other challenging therapeutic areas.

01.29.24

APIs | Cytotoxics and High Potency Manufacturing

Trends in the Development of ADCs

Targeting tumor heterogeneity with antibody-drug conjugates and novel payloads.

Louise Duffy, Chief Technical Officer, Abzena 01.25.24

APIs | Cytotoxics and High Potency Manufacturing

API Market Trends

Companies are looking to diversify their API suppliers and manufacturers to different locations instead of outsourcing it to just one manufacturer.

Online Exclusives Grand View Research 01.25.24

Breaking News | Cytotoxics and High Potency Manufacturing | Drug Development | Drug Discovery | Industry News

Experic Installs New Capsule Filling Machine at New Jersey Facility

Provides enhanced protection of employees and the environment from highly potent pharmaceutical products.

12.07.23

Cytotoxics and High Potency Manufacturing

Developing HPAPIs: Leveraging Classification Systems to Mitigate Risk

Exploring the importance of robust classification systems to accurately characterize and classify HPAPIs for safe handling.

Catherine Wilkes, Executive Director of Environmental, Health & Safety, Quotient Sciences 11.14.23

Cytotoxics and High Potency Manufacturing

ABCs of ADCs: A Brief Primer

Reviewing some pros and cons that exist within the outsourcing realm for antibody drug conjugates.

Ben Locwin , Contributing Editor 11.14.23

cGMP Manufacture | Cytotoxics and High Potency Manufacturing

The Evolution of HPAPI Manufacturing for CDMOs

The demand for highly potent APIs has been steadily increasing, driven by the development of targeted therapies in oncology and other disease areas.

Adam Kujath, EVP and Site Head, Germantown, Sterling Pharma Solutions 10.12.23

cGMP Manufacture | Cytotoxics and High Potency Manufacturing

"3 Key Trends" with Srinivasan Shanmugam

Adare Pharma Solutions’ Senior Director of Pharmaceutical Sciences, Business Support, and New Technologies offers his thought leadership.

Online Exclusives Contract Pharma 09.28.23

Cytotoxics and High Potency Manufacturing | Facilities

HPAPI Manufacturing Trends

Oncology drugs, advancements in manufacturing technology, and a rise in capacity to meet greater demand drive market growth.

Tim Wright, Editor, Contract Pharma 09.13.23

Cytotoxics and High Potency Manufacturing | Drug Development

"3 Key Trends" with Louise Duffy

Abzena’s Chief Technical Officer offers her thought leadership.

Online Exclusives Contract Pharma 08.04.23

Talking Toxicology for Safer HPAPIs

Toxicological evaluation is important at every stage of HPAPI development and manufacturing—CDMOs help ensure new treatments are brought to market safely.

Sponsored released by Evonik 07.20.23

Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News

WuXi STA Debuts First HP Sterile Injectable Mfg. Line at Wuxi Site

Annual capacity of 12 million units enhances manufacturing capabilities and capacity for injectable dosage forms.

07.18.23

Breaking News | Clinical Trial Materials | Cytotoxics and High Potency Manufacturing | Drug Development | Industry News

NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer

NorthStar’s non-carrier added Ac-225 to be used in Bayer’s radiopharmaceutical programs.

07.18.23

APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News

Aenova Opens New Building for Highly Potent Drugs

Makes total investment of around €25 million at the Regensburg site to increase development and production capacities.

06.23.23

OLON Enters ADC Market

Invests €22 million in a new facility dedicated to ultra-potent compounds.

05.30.23

AmbioPharm Expands South Carolina Headquarters

Includes increasing synthesis capacity and supporting growth in late phase and commercial production.

05.18.23

Login

Join

FOLLOW:

Subscribe Free

Magazine

eNewsletter

Checkout